Earlier this week, Bio-Thera Solutions announced the initiation of the Phase III clinical study for its tocilizumab biosimilar, BAT1806. According to the press release, the Phase III clinical study will enroll over 65 patients at more than 45 sites around the world, and will compare the safety and efficacy of…
During the first weeks of 2019 a number of biosimilar developers announced updates regarding their plans for the future. Bio-Thera Solutions Partners with Cipla for Bevacizumab Biosimilar Candidate On January 14, 2019, Bio-Thera Solutions Ltd announced that it has entered into a licensing agreement with Cipla Limited for BAT-1706, its…